.Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GA07_Brimonidine.Brimonidine .Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GA07_Brimonidine.Brimonidine| name: | Brimonidine |
| ATC code: | S01GA07 | route: | ophthalmic |
| n-compartments | 1 |
Brimonidine is an alpha-2 adrenergic receptor agonist used primarily in ophthalmology to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as an ophthalmic solution and is an approved and currently used drug.
Pharmacokinetic parameters in adults following topical ocular administration under steady-state conditions.
Ackerman, SL, et al., & Vittitow, JL (2019). Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clinical & experimental optometry 102(2) 131–139. DOI:10.1111/cxo.12846 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30525235
Schnichels, S, et al., & Herrmann, A (2021). Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. ACS applied materials & interfaces 13(8) 9445–9456. DOI:10.1021/acsami.0c18626 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33528240
Kim, CY, et al., & Seong, GJ (2007). Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 23(5) 481–486. DOI:10.1089/jop.2007.0042 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17900227